Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 3,344 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the transaction, the insider now owns 102,766 shares in the company, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total value of $392,786.08.

Insmed Stock Performance

Shares of INSM stock opened at $65.25 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company’s fifty day moving average price is $71.23 and its two-hundred day moving average price is $72.42. The firm has a market capitalization of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The business’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter last year, the business posted ($1.10) EPS. On average, research analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of Insmed by 4.7% in the third quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock worth $278,432,000 after buying an additional 172,664 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in Insmed during the 2nd quarter worth $237,076,000. Principal Financial Group Inc. grew its holdings in Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after acquiring an additional 214,130 shares in the last quarter. Clearbridge Investments LLC increased its position in shares of Insmed by 76.8% in the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after purchasing an additional 714,539 shares during the last quarter. Finally, Vestal Point Capital LP raised its stake in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on INSM shares. JPMorgan Chase & Co. boosted their price target on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and an average target price of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.